Skip to main content
An exciting mining stock opportunity in the outback
With the gold price back on track, this could be the best time for a very close look at this outstanding mining company
Learn More

DBTX Insider Trading (Decibel Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $13,050,000.00
Insider Selling (Last 12 Months): $0.00

Decibel Therapeutics Insider Trading History Chart

Decibel Therapeutics Share Price & Price History

▼ -0.54 (-6.78%)
As of 05/6/2021 01:00 AM ET
Days: 30 | 90 | 365
Major Stock Growth Alert
The top US biotech penny stock in the hottest market has an edge over its competitors
Click to get your free report

Decibel Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/17/2021Casdin Partners Master Fund, LMajor ShareholderBuy575,000$18.00$10,350,000.00View SEC Filing Icon  
2/17/2021Plc GlaxosmithklineDirectorBuy150,000$18.00$2,700,000.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Decibel Therapeutics (NASDAQ:DBTX)

Decibel Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/4/2021Victory Capital Management Inc.51,139$0.58M0.0%N/A0.205%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Decibel Therapeutics logo
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts.
Read More on Decibel Therapeutics

Today's Range

Now: $7.42

50 Day Range

MA: $10.93

52 Week Range

Now: $7.42


52,521 shs

Average Volume

149,302 shs

Market Capitalization

$184.77 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Decibel Therapeutics?

Decibel Therapeutics' top insider shareholders include:
  1. Casdin Partners Master Fund, L (Major Shareholder)
  2. Plc Glaxosmithkline (Director)

Who are the major institutional investors of Decibel Therapeutics?

Decibel Therapeutics' top institutional investors include:
  1. Victory Capital Management Inc. — 0.21%

Which institutional investors are buying Decibel Therapeutics stock?

In the previous quarter, DBTX stock was purchased by institutional investors including:
  1. Victory Capital Management Inc.
In the last year, these company insiders have bought Decibel Therapeutics stock:
  1. Casdin Partners Master Fund, L (Major Shareholder)
  2. Plc Glaxosmithkline (Director)
Massive land holdings yield chance for next gold discovery
Right next door to Kirkland Lake´s famous Fosterville Mine, read what geologist Byron King thinks about this exciting new gold opportunity
Find out which stock we´re talking about